In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences, with a price target of $28.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yaron Werber’s rating is based on several promising developments within Roivant Sciences. The company has shown significant progress with its brepocitinib and batoclimab programs, which are expected to yield important data in the coming years. Brepocitinib’s recent Phase 3 success in dermatomyositis supports an NDA filing in the first half of 2026, with further potential in non-infectious uveitis and cutaneous sarcoidosis. Additionally, batoclimab’s Phase 2 data in Graves’ disease is encouraging, providing validation for IMVT-1402, which is expected to deliver Phase 3 data in thyroid eye disease by the first half of 2026.
Furthermore, Roivant’s strong cash position of $4.4 billion offers a solid runway to profitability, supporting its ambitious pipeline. The company is also expected to present more detailed opportunities in Graves’ disease during an upcoming Investor Day. The combination of these factors, along with an increased price target of $28, up from $23, reflects a positive outlook for Roivant Sciences, justifying the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
Based on the recent corporate insider activity of 117 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ROIV in relation to earlier this year.